Javascript must be enabled to continue!
Implementing a clinical ethics support instrument for palliative care (CURA): facilitators, barriers, and strategies
View through CrossRef
Abstract
Background
To support healthcare professionals in dealing with moral challenges in palliative care, CURA, a clinical ethics support instrument, was developed. The aim of the present study is to identify facilitators for and barriers to the implementation of CURA in healthcare organizations, and to identify strategies for improving the implementation of CURA.
Methods
Design: We used a mixed-method design combining quantitative and qualitative methods (a questionnaire and group interviews).
Setting: 13 healthcare facilities in which palliative care is provided and in which CURA is implemented: three general hospitals, five nursing homes, two hospices, three home care organizations.
Data collection and participants: The quantitative part of the study comprised a questionnaire with determinants for successful implementation. Data were obtained 18 months after the start of implementation. Respondents were 47 care providers who were trained as so-called ‘CURA ambassadors’, i.e., pioneers in initiating, facilitating and implementing CURA in their organization. The qualitativepart of the study consisted of both open questions to the respondents to the questionnaire and three group interviews (total n=10).
Analysis: Quantitative data of the questionnaire were analyzed descriptively. Qualitative data were analysed using both deductive content analysis on main themes and inductive content analysis on subthemes.
Results
We identified facilitators, barriers and strategies at four levels of implementation: intervention, users, organization, and socio-political context. Important facilitators pertain to CURA’s time efficiency, perceived effectiveness, attitude and competences of CURA ambassadors, commitment and support from colleagues and management. Major barriers were a lack of (allocation of) time, and resistance towards new interventions in the organization. Strategies pertain to embedding the use of CURA in existing structures, and pro-actively convincing colleagues and management of the benefits of using CURA.
Conclusions
Our research on the implementation of CURA, adds to the scarce knowledge that we have on how to implement clinical ethics support in healthcare organizations. Our findings provide concrete suggestions to organizations providing palliative care that seek to implement CURA, such as using evidence on the effectiveness of CURA to convince management, or to embed the use of CURA during meetings that are already scheduled and part of work routines.
Springer Science and Business Media LLC
Title: Implementing a clinical ethics support instrument for palliative care (CURA): facilitators, barriers, and strategies
Description:
Abstract
Background
To support healthcare professionals in dealing with moral challenges in palliative care, CURA, a clinical ethics support instrument, was developed.
The aim of the present study is to identify facilitators for and barriers to the implementation of CURA in healthcare organizations, and to identify strategies for improving the implementation of CURA.
Methods
Design: We used a mixed-method design combining quantitative and qualitative methods (a questionnaire and group interviews).
Setting: 13 healthcare facilities in which palliative care is provided and in which CURA is implemented: three general hospitals, five nursing homes, two hospices, three home care organizations.
Data collection and participants: The quantitative part of the study comprised a questionnaire with determinants for successful implementation.
Data were obtained 18 months after the start of implementation.
Respondents were 47 care providers who were trained as so-called ‘CURA ambassadors’, i.
e.
, pioneers in initiating, facilitating and implementing CURA in their organization.
The qualitativepart of the study consisted of both open questions to the respondents to the questionnaire and three group interviews (total n=10).
Analysis: Quantitative data of the questionnaire were analyzed descriptively.
Qualitative data were analysed using both deductive content analysis on main themes and inductive content analysis on subthemes.
Results
We identified facilitators, barriers and strategies at four levels of implementation: intervention, users, organization, and socio-political context.
Important facilitators pertain to CURA’s time efficiency, perceived effectiveness, attitude and competences of CURA ambassadors, commitment and support from colleagues and management.
Major barriers were a lack of (allocation of) time, and resistance towards new interventions in the organization.
Strategies pertain to embedding the use of CURA in existing structures, and pro-actively convincing colleagues and management of the benefits of using CURA.
Conclusions
Our research on the implementation of CURA, adds to the scarce knowledge that we have on how to implement clinical ethics support in healthcare organizations.
Our findings provide concrete suggestions to organizations providing palliative care that seek to implement CURA, such as using evidence on the effectiveness of CURA to convince management, or to embed the use of CURA during meetings that are already scheduled and part of work routines.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Harmonizing Palliative Care: National Survey to Evaluate the Knowledge and Attitude of Emergency Physicians towards Palliative Care
Harmonizing Palliative Care: National Survey to Evaluate the Knowledge and Attitude of Emergency Physicians towards Palliative Care
Background and Aim
Although the challenges of integrating palliative care practices across care settings are real and well recognized until now little is known ab...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Building Primary Palliative Care Capacity Through Education at a National Level: Pallium Canada and its LEAP Courses
Building Primary Palliative Care Capacity Through Education at a National Level: Pallium Canada and its LEAP Courses
Background All the palliative care needs of a population cannot be met by specialist palliative care clinicians and teams alone. Both primary-level and specialist-level palliative ...
Specialised Palliative Care in Day Clinic, Hospital Unit or at Home: Which for Whom and When? A Retrospective Routine Data Analysis
Specialised Palliative Care in Day Clinic, Hospital Unit or at Home: Which for Whom and When? A Retrospective Routine Data Analysis
Background:
Palliative care units and specialised palliative home care teams are well established in many countries. Palliative day-care clinics, however, are n...
Dementia patients in palliative care according to data from the German National Hospice and Palliative Care Register (2009–2021)
Dementia patients in palliative care according to data from the German National Hospice and Palliative Care Register (2009–2021)
Abstract
Background
People with dementia are less in focus of palliative care research than other patient groups even though the awareness of their ...

